Bio Plus Co., Ltd (KOSDAQ:099430)
South Korea · Delayed Price · Currency is KRW 5,260.00
+110.00 (2.14%)
Apr 10, 2026, 3:30 PM KST
Bio Plus Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 90,896 | 66,410 | 65,043 | 56,719 | 37,418 |
Other Revenue | -0 | -0 | - | - | - |
| 90,896 | 66,410 | 65,043 | 56,719 | 37,418 | |
Revenue Growth (YoY) | 36.87% | 2.10% | 14.68% | 51.58% | 53.56% |
Cost of Revenue | 30,359 | 23,865 | 25,525 | 22,942 | 13,790 |
Gross Profit | 60,537 | 42,545 | 39,518 | 33,776 | 23,628 |
Selling, General & Admin | 35,255 | 14,172 | 8,170 | 6,534 | 4,339 |
Research & Development | 3,394 | 1,477 | 1,165 | 1,081 | 435.18 |
Amortization of Goodwill & Intangibles | 391.63 | 436.81 | 340.2 | 203.14 | 111.76 |
Other Operating Expenses | 670.1 | 213.17 | 155.02 | 59.11 | 11.46 |
Operating Expenses | 45,548 | 18,878 | 11,493 | 8,176 | 5,402 |
Operating Income | 14,989 | 23,667 | 28,026 | 25,600 | 18,226 |
Interest Expense | -303.65 | -263.43 | -60.28 | -13.3 | -521.47 |
Interest & Investment Income | 590.33 | 1,796 | 2,439 | 1,074 | 158.26 |
Earnings From Equity Investments | -212.48 | - | - | -311.08 | -327.99 |
Currency Exchange Gain (Loss) | -95.28 | 1,625 | 200.64 | 461.34 | 304.74 |
Other Non Operating Income (Expenses) | 2,319 | -8,037 | 2,103 | 129.56 | -2,107 |
EBT Excluding Unusual Items | 17,286 | 18,788 | 32,708 | 26,941 | 15,733 |
Gain (Loss) on Sale of Investments | 326.27 | 87.62 | 41.03 | 639.04 | - |
Gain (Loss) on Sale of Assets | -1.33 | 592.74 | -8.52 | -81.04 | - |
Asset Writedown | -74.49 | - | - | -28.02 | -1,565 |
Other Unusual Items | - | -1,804 | - | - | - |
Pretax Income | 17,536 | 17,664 | 32,740 | 27,471 | 14,168 |
Income Tax Expense | -2,460 | 153.09 | 5,318 | 6,763 | 3,495 |
Earnings From Continuing Operations | 19,996 | 17,510 | 27,422 | 20,708 | 10,673 |
Minority Interest in Earnings | -4,995 | -3,359 | -1,841 | 428.96 | 51.68 |
Net Income | 15,001 | 14,151 | 25,581 | 21,137 | 10,725 |
Net Income to Common | 15,001 | 14,151 | 25,581 | 21,137 | 10,725 |
Net Income Growth | 6.01% | -44.68% | 21.02% | 97.09% | 10.53% |
Shares Outstanding (Basic) | 59 | 57 | 58 | 57 | 52 |
Shares Outstanding (Diluted) | 101 | 57 | 61 | 57 | 52 |
Shares Change (YoY) | 75.73% | -5.44% | 5.64% | 10.68% | 3.82% |
EPS (Basic) | 253.00 | 249.00 | 444.85 | 371.84 | 207.02 |
EPS (Diluted) | 149.00 | 247.00 | 433.36 | 371.18 | 206.94 |
EPS Growth | -39.68% | -43.00% | 16.75% | 79.36% | 9.64% |
Free Cash Flow | -28,927 | -68,513 | -803.37 | 6,829 | -1,959 |
Free Cash Flow Per Share | -287.31 | -1195.85 | -13.26 | 119.07 | -37.80 |
Dividend Per Share | - | - | 70.000 | 70.000 | - |
Gross Margin | 66.60% | 64.07% | 60.76% | 59.55% | 63.15% |
Operating Margin | 16.49% | 35.64% | 43.09% | 45.14% | 48.71% |
Profit Margin | 16.50% | 21.31% | 39.33% | 37.27% | 28.66% |
Free Cash Flow Margin | -31.82% | -103.17% | -1.23% | 12.04% | -5.24% |
EBITDA | 19,052 | 26,937 | 30,516 | 27,487 | 19,524 |
EBITDA Margin | 20.96% | 40.56% | 46.92% | 48.46% | 52.18% |
D&A For EBITDA | 4,063 | 3,270 | 2,490 | 1,887 | 1,298 |
EBIT | 14,989 | 23,667 | 28,026 | 25,600 | 18,226 |
EBIT Margin | 16.49% | 35.64% | 43.09% | 45.14% | 48.71% |
Effective Tax Rate | - | 0.87% | 16.24% | 24.62% | 24.67% |
Advertising Expenses | 1,609 | 1,045 | 230.71 | 228.49 | 32.22 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.